A Phase 1b/2a, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
Phase of Trial: Phase I/II
Latest Information Update: 14 Jul 2016
At a glance
- Drugs APN 1125 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors CoMentis
- 11 Jul 2016 Status changed from recruiting to suspended.
- 18 Apr 2016 Status changed from not yet recruiting to recruiting.
- 05 Apr 2016 New trial record